EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Evidence-Based Medicine 2006;11:175; doi:10.1136/ebm.11.6.175
Copyright © 2006 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, B.
Topic Collections
Right arrowRelevant Article

Therapeutics

Esomeprazole did not universally improve asthma outcomes in moderate to severe stable asthma

Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2006;173:1091–7.[Abstract/Free Full Text]

Q In patients with moderate to severe stable asthma, does treatment with esomeprazole improve asthma outcomes?

Clinical impact ratings GP/FP/Primary care *****{star}{star} IM/Ambulatory care *****{star}{star} Gastroenterology ******{star} Respirology *****{star}{star}

Key Words: asthma • gastro-oesophageal reflux • omeprazole

The first 150 words of the full text of this article appear below.

METHODS
Formula Design: randomised, placebo controlled trial.

Formula Allocation: {concealed*}{dagger}.

Formula Blinding: blinded {patients, healthcare providers, data collectors, outcome assessors, data analysts, monitoring committee, and manuscript writers}{dagger}.*

Formula Follow up period: 16 weeks.

Formula Setting: 122 centres in North and South America and Europe.

Formula Patients: 770 patients 18–70 years of age (mean age 45 y, 70% women) with stable, adequately treated asthma, FEV1 50–80% of predicted with >=12% reversibility, and mean morning peak expiratory flow (PEF) <80% predicted. Exclusion criteria included recent use of a proton pump inhibitor and recurrent moderate to severe symptoms of gastro-oesophageal reflux disease (GORD) in patients >40 years of age. During the run in period, patients were excluded if they had >20% decrease in FEV1, or severe exacerbations of GORD or nocturnal respiratory (NOC) or asthma symptoms. Patients were stratified into those with NOC (n = 201), GORD (n = 219), or both NOC and GORD (n . . . [Full text of this article]

Brian Smith, MD

The Queen Elizabeth Hospital, Adelaide, South Australia, Australia


Relevant Article

Glossary
Evid. Based Med. 2006 11: 191. (in Glossary) [Extract] [Full Text] [PDF]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd.